BioCentury | Apr 22, 2021
Emerging Company Profile

Code Bio: Using DNA scaffolds to deliver non-viral gene therapies

...as well as other gene therapies in clinical testing, such as the micro-dystrophin-targeting therapy from Sarepta Therapeutics Inc....
BioCentury | Apr 10, 2021
Finance

1Q21 Wrap: Sliding down

...full-screen mode, please select that option from three dots on Google Slides bar. Meredith Durkin Wolfe BeiGene Ltd. Sarepta Therapeutics Inc. Novavax...
BioCentury | Apr 2, 2021
Management Tracks

O’Brien to head NPC; plus moves at Frontier, Araris, Montis and more

...BioSolutions Inc. (NYSE:EBS) and Fernandes was senior director of data compliance and chief privacy officer at Sarepta Therapeutics Inc....
BioCentury | Mar 31, 2021
Emerging Company Profile

Entrada: Moving cell-penetrating DMD therapy into clinic with $116M series B

...enter a market that already has three approved exon-skipping phosphorodiamidate morpholino oligomer (PMO) therapies from Sarepta Therapeutics Inc....
BioCentury | Mar 17, 2021
Management Tracks

High-profile departures at Sage, bluebird as Cloonan, Davidson depart; plus CBC Group, Turning Point, Agilent, Intercept, Centessa, Beam and more

...Howton as COO and general counsel. Howton was EVP of legal and general counsel at Sarepta Therapeutics Inc....
BioCentury | Mar 17, 2021
Deals

March 17 Quick Takes: Merck-Amathus enter neurodegenerative disease collaboration; plus WuXi, Sana-Fujifilm, Rubius, Inflammatix, StrideBio and more

...round co-led by Northpond Ventures and Novo Holdings A/S and included new investors Pontifax, Octagon Capital, Sarepta Therapeutics...
BioCentury | Mar 6, 2021
Product Development

The pace of new modality approvals is picking up

...dominated by two companies, Ionis Pharmaceuticals Inc. (NASDAQ:IONS) and Sarepta Therapeutics Inc....
BioCentury | Mar 2, 2021
Politics, Policy & Law

Whither Woodcock; plus refresh for German biotech & modalities to market: a BioCentury podcast

...of Duchenne muscular dystrophy therapy Amondys 45 from Sarepta Therapeutics Inc....
BioCentury | Feb 26, 2021
Deals

Feb. 25 Quick Takes: AveXis execs, Deerfield launch Jaguar plus one; Sarepta DMD approval, Apollomics IPO plans and Sirion-Sanofi, an Oxford pair and DeuterOncology

...and RAS pathway inhibitor the company believes could overcome resistance to approved MET inhibitors. Jeff Cranmer AveXis Inc. Deerfield Sarepta Therapeutics Inc. Apollomics...
BioCentury | Feb 19, 2021
Finance

Evox eyes clinic for internal pipeline with £69.2M series C round

...mid-2021 and could constitute the first human proof of concept for exosome therapies.Codiak partnered with Sarepta Therapeutics Inc....
Items per page:
1 - 10 of 746
BioCentury | Apr 22, 2021
Emerging Company Profile

Code Bio: Using DNA scaffolds to deliver non-viral gene therapies

...as well as other gene therapies in clinical testing, such as the micro-dystrophin-targeting therapy from Sarepta Therapeutics Inc....
BioCentury | Apr 10, 2021
Finance

1Q21 Wrap: Sliding down

...full-screen mode, please select that option from three dots on Google Slides bar. Meredith Durkin Wolfe BeiGene Ltd. Sarepta Therapeutics Inc. Novavax...
BioCentury | Apr 2, 2021
Management Tracks

O’Brien to head NPC; plus moves at Frontier, Araris, Montis and more

...BioSolutions Inc. (NYSE:EBS) and Fernandes was senior director of data compliance and chief privacy officer at Sarepta Therapeutics Inc....
BioCentury | Mar 31, 2021
Emerging Company Profile

Entrada: Moving cell-penetrating DMD therapy into clinic with $116M series B

...enter a market that already has three approved exon-skipping phosphorodiamidate morpholino oligomer (PMO) therapies from Sarepta Therapeutics Inc....
BioCentury | Mar 17, 2021
Management Tracks

High-profile departures at Sage, bluebird as Cloonan, Davidson depart; plus CBC Group, Turning Point, Agilent, Intercept, Centessa, Beam and more

...Howton as COO and general counsel. Howton was EVP of legal and general counsel at Sarepta Therapeutics Inc....
BioCentury | Mar 17, 2021
Deals

March 17 Quick Takes: Merck-Amathus enter neurodegenerative disease collaboration; plus WuXi, Sana-Fujifilm, Rubius, Inflammatix, StrideBio and more

...round co-led by Northpond Ventures and Novo Holdings A/S and included new investors Pontifax, Octagon Capital, Sarepta Therapeutics...
BioCentury | Mar 6, 2021
Product Development

The pace of new modality approvals is picking up

...dominated by two companies, Ionis Pharmaceuticals Inc. (NASDAQ:IONS) and Sarepta Therapeutics Inc....
BioCentury | Mar 2, 2021
Politics, Policy & Law

Whither Woodcock; plus refresh for German biotech & modalities to market: a BioCentury podcast

...of Duchenne muscular dystrophy therapy Amondys 45 from Sarepta Therapeutics Inc....
BioCentury | Feb 26, 2021
Deals

Feb. 25 Quick Takes: AveXis execs, Deerfield launch Jaguar plus one; Sarepta DMD approval, Apollomics IPO plans and Sirion-Sanofi, an Oxford pair and DeuterOncology

...and RAS pathway inhibitor the company believes could overcome resistance to approved MET inhibitors. Jeff Cranmer AveXis Inc. Deerfield Sarepta Therapeutics Inc. Apollomics...
BioCentury | Feb 19, 2021
Finance

Evox eyes clinic for internal pipeline with £69.2M series C round

...mid-2021 and could constitute the first human proof of concept for exosome therapies.Codiak partnered with Sarepta Therapeutics Inc....
Items per page:
1 - 10 of 746